深度学习平台aPROMISE与标准阅片器评估PSMA PET/CT的对比及组织病理学验证
本研究回顾性分析96例前列腺切除后生化持续或复发患者的[68Ga]Ga-PSMA-I&T PET/CT,由2名阅片者分别使用标准阅片器ISP和深度学习分割报告软件aPROMISE各评估两次,并与PSMA引导手术的组织病理学对照。两种系统的阅片者内和阅片者间一致性均较高,aPROMISE自动分割了共识识别的140个病灶中的129个(92.1%),影像与病理一致性较高(≥86.5%)。人工智能软件可作为早期前列腺癌PSMA PET/CT评估的支持工具。
要点
- ISP与aPROMISE的阅片者内和阅片者间一致性均较高(≥91.7%和≥92.2%)。
- aPROMISE自动分割了共识识别140个病灶中的129个(92.1%)。
- 影像与病理一致性≥86.5%,但33例(34.4%)存在重大分期差异。
核心结论
- ISP和aPROMISE对PSMA PET/CT评估的阅片者内和阅片者间一致性相似且均较高。
- aPROMISE算法分割了所有识别病灶的92.1%。
- 人工智能软件可作为早期前列腺癌PSMA PET/CT评估的支持工具。
研究设计与样本
- 回顾性分析96例前列腺切除后生化持续或复发患者的[68Ga]Ga-PSMA-I&T PET/CT。
- 患者中位前列腺特异性抗原为0.56 ng/mL(四分位距0.31-1.24 ng/mL),均接受PSMA引导手术。
- 2名阅片者分别使用ISP评估两次、aPROMISE评估两次,以组织病理学为标准真值。
主要发现
- 阅片者内一致率所有类别、两名阅片者和两种系统均≥91.7%,κ值中等到几乎完美(阅片者1 ISP ≥0.51,范围0.21-0.9;aPROMISE ≥0.64,范围0.41-0.99;阅片者2 ISP ≥0.83,范围0.69-1;aPROMISE ≥0.78,范围0.63-1)。
- 重大差异在阅片者1比阅片者2更常见(ISP 26% vs. 13.5%;aPROMISE 22.9% vs. 12.5%)。
- 阅片者间一致率两种系统均≥92.2%,κ值显著(ISP ≥0.73,范围0.47-0.99;aPROMISE ≥0.74,范围0.54-1),21例(21.9%)存在重大miTNM分期差异。
- 阅片者共识识别140个病灶,aPROMISE自动分割129个(92.1%);未分割病灶毗邻高尿活性或PSMA表达低。
- 影像与病理一致率≥86.5%,κ值中等到显著(≥0.6,范围0.45-1),33例(34.4%)存在重大分期差异,其中13例(13.5%)有影像靶区外的远处转移,仅1个被aPROMISE自动分割。
临床怎么用
- aPROMISE可作为PSMA PET/CT评估的辅助工具,提高分割效率。
- 需注意算法可能漏分割毗邻高尿活性或低PSMA表达的病灶。
- 影像与病理存在重大分期差异,临床决策需结合组织病理学验证。
局限性
- 回顾性研究设计。
- 单中心研究。
- 样本量96例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Standardized prostate-specific membrane antigen (PSMA) PET/CT evaluation and reporting was introduced to aid interpretation, reproducibility, and communication. Artificial intelligence may enhance these efforts. This study aimed to evaluate the performance of aPROMISE, a deep learning segmentation and reporting software for PSMA PET/CT, compared with a standard image viewer (IntelliSpace Portal [ISP]) in patients undergoing PSMA-radioguided surgery. This allowed the correlation of target lesions with histopathology as a standard of truth. Methods: [68Ga]Ga-PSMA-I&T PET/CT of 96 patients with biochemical persistence or recurrence after prostatectomy (median prostate-specific antigen, 0.56 ng/mL; interquartile range, 0.31-1.24 ng/mL), who underwent PSMA-radioguided surgery, were retrospectively analyzed (twice with ISP and twice with aPROMISE) by 2 readers. Cohen κ with 95% CI was calculated to assess intra- and interrater agreement for miTNM stages. Differences between miTNM codelines were classified as no difference, minor difference (change of lymph node region without N/M change), and major difference (miTNM change). Results: Intrarater agreement rates were high for all categories, both readers, and systems (≥91.7%) with moderate to almost perfect κ values (reader 1, ISP, ≥0.51; range, 0.21-0.9; aPROMISE, ≥0.64; range, 0.41-0.99; reader 2, ISP, ≥0.83; range, 0.69-1; aPROMISE, ≥0.78; range, 0.63-1). Major differences occurred more frequently for reader 1 than for reader 2 (ISP, 26% vs. 13.5%; aPROMISE, 22.9% vs. 12.5%). Interrater agreement rates were high with both systems (≥92.2%), demonstrating substantial κ values (ISP, ≥0.73; range, 0.47-0.99; aPROMISE, ≥0.74; range, 0.54-1) with major miTNM staging differences in 21 (21.9%) cases. Readers identified 140 lesions by consensus, of which aPROMISE automatically segmented 129 (92.1%) lesions. Unsegmented lesions either were adjacent to high urine activity or demonstrated low PSMA expression. Agreement rates between imaging and histopathology were substantial (≥86.5%), corresponding to moderate to substantial κ values (≥0.6; range, 0.45-1) with major staging differences in 33 (34.4%) patients. This included 13 (13.5%) cases with metastases distant from targets identified on imaging. One of these lesions was automatically segmented by aPROMISE. Conclusion: Intra- and interreader agreement for PSMA PET/CT evaluation were similarly high with ISP and aPROMISE. The algorithm segmented 92.1% of all identified lesions. Software applications with artificial intelligence could be applied as support tools in PSMA PET/CT evaluation of early prostate cancer.
引用
- Koehler D, Shenas F, Sauer M, et al. PSMA PET Evaluation with a Deep Learning Platform Compared with a Standard Image Viewer and Histopathology. J Nucl Med. 2025. PMID: 41101977. doi:10.2967/jnumed.125.270242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。